FLX475 Terminated Phase 2 Trials for Advanced Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04894994FLX475 in Combination With Ipilimumab in Advanced Melanoma